Newly published data from a study combining Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab) and Eisai Co., Ltd.’s multiple tyrosine kinase inhibitor Lenvima (lenvatinib) in endometrial carcinoma adds to Keytruda’s growing repertoire of data in women’s cancers. With recent approvals in key settings of cervical cancer and triple-negative breast cancer (TNBC), Keytruda has taken a lead in cancers affecting women, even as other players played catch-up or stumbled.
Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data
Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.
More from Anticancer
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
More from Therapy Areas
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.